「BiTE Amgen」熱門搜尋資訊

BiTE Amgen

「BiTE Amgen」文章包含有:「BiTE®Molecule」、「BiTE®Molecule」、「BiTE®Immuno」、「HLEBiTE®Molecule」、「BiTE®Technology101」、「BiTEInteractive」、「BiTEtheEngager™」、「BiTEtheEngager」、「T細胞銜接有何魅力?MSD攜手Janux!Roche」

查看更多
Provide From Google
BiTE® Molecule
BiTE® Molecule

https://www.amgenoncology.com

The BiTE® immuno-oncology platform offers versatility to potentially target any tumor-associated antigen. The BiTE® platform is being studied across a wide ...

Provide From Google
BiTE® Molecule
BiTE® Molecule

https://www.amgen.com

A BiTE® antibody construct is a type of fusion protein that is designed to harness the power of the immune system to treat cancer.

Provide From Google
BiTE® Immuno
BiTE® Immuno

https://www.amgenoncology.com

Amgen is pioneering BiTE® technology to advance the immuno-oncology field and bring new therapeutic approaches to patients. Features of the BiTE® platform.

Provide From Google
HLE BiTE® Molecule
HLE BiTE® Molecule

https://www.amgenoncology.com

Canonical BiTE® molecules are relatively small recombinant proteins that can be eliminated by the kidneys and have a serum half-life of a few hours. Currently, ...

Provide From Google
BiTE® Technology 101
BiTE® Technology 101

https://www.amgen.com

BiTE molecules can be designed to engage the body's immune system against specific targets found in some cancers. BiTE technology is a novel ...

Provide From Google
BiTE Interactive
BiTE Interactive

https://www.amgenoncology.com

BiTE® immuno-oncology technology is designed to overcome these evasive mechanisms by binding directly to surface antigens on the targeted cancer cell.

Provide From Google
BiTE the Engager™
BiTE the Engager™

https://www.amgenoncology.com

The growing BiTE® immuno-oncology pipeline9. *HLE BiTE® Platform. AMGEN IS. COMMITTED TO. BRINGING T-CELL. INNOVATION TO. PATIENTS. Acapatamab (AMG 160)*. PSMA.

Provide From Google
BiTE the Engager
BiTE the Engager

https://www.amgenoncology.com

• Pioneered by Amgen, who continues to accelerate the investigation of BiTE® technology with the goal of enhancing patient experience and therapeutic ...

Provide From Google
T 細胞銜接有何魅力? MSD 攜手Janux!Roche
T 細胞銜接有何魅力? MSD 攜手Janux!Roche

https://geneonline.news

Amgen 透過銜接2 種抗體的標靶區域來創建這些雙特異性分子BiTE。該分子的一個臂被設計為與細胞毒性T 細胞表面上發現的蛋白質結合,另一臂被設計為與主要在 ...